Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
View in:
PubMed
subject areas
Adenine
Antineoplastic Agents
Cell Transformation, Neoplastic
DNA Mutational Analysis
Drug Resistance, Neoplasm
Female
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Middle Aged
Mutation
Neoplasm Recurrence, Local
Piperidines
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrazoles
Pyrimidines
src Homology Domains
authors with profiles
Girish Venkataraman
Jeremy Segal
Wendy Stock
Wei-Jen Tang